checkAd
    EyePoint Pharmaceuticals Aktie
    0,9730
     
    EUR
    +2,85 %
    +0,0270 EUR
    Letzter Kurs 05.04.18 Tradegate
    0,9580
     
    EUR
    3.134 STK
    Geldkurs 05.04.18
    0,9880
     
    EUR
    3.034 STK
    Briefkurs 05.04.18
    ISIN: US74440J1016 · WKN: A0Q4DQ · USA

    Neueste Nachrichten

    EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    16.05.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
    08.05.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy
    06.05.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    16.04.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
    02.04.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    18.03.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
    07.03.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
    04.03.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
    29.02.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
    27.02.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    16.02.24 · globenewswire · EyePoint Pharmaceuticals
    EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
    03.02.24 · globenewswire · EyePoint Pharmaceuticals